THE TAPE
SOLV · Medical Instruments · $15.1B

Solventum Corporation

$88.65▼ −0.48%
Last close
Relative strength
64RS
of 99, against every stock▼ -9 on the month
Cooling off
Strong industry, weak stock
−11.3%
six months against Medical Instruments
52-week range
−5.9%
from the high
$62.38$94.16
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth WEAKProof PENDING
Quarter to Sep 30, revenue −7% on a year ago
Why it is on no screen

SOLV is off the screens on one check: relative strength.

A base has formed10.8 weeks, from 80.76 to 94.16.
Long enough to count10.8 weeks against 3 needed.
Shallow enough14.2% deep against 35% allowed.
Close to its pivot-5.9% from the pivot; listed down to -20%.
Relative strengthRS 64 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$87.43
-1.4% · tested 8× · last 2 sessions ago
Resistance above
$89.67
+1.2% · tested 7× · last 22 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Solventum Corporation is not on any of the screens right now. Its relative strength rating is 64, and it sits in Medical Instruments.

Against its industry
Strong industry, weak stockBehind its industry over one and six months while the industry is fully aligned and ahead of the S&P 500.
One month against its industry
-0.8%
Three months against its industry
+1.2%
Six months against its industry
-11.3%

Read against an equal-weighted index of Medical Instruments, which is +31.0% against the S&P 500 over six months Fully aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 4.0% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$8.2B
-7.0% year on year
Operating margin
5.6%
gross 54.8%
Net margin
1.9%
Free cash flow
—
0.0% of market cap
Price to sales
1.85×
Price to earnings
96.7×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 5
Key takeaway
Revenue is falling but the business still generates cash.
Revenue
$1.9B
-11.8% QoQ · -7.0% YoY
Gross margin
54.5%
-3.7 pts QoQ
Net income
−$12.0M
Loss
Free cash flow
$97.0M
Cash generating

What the numbers say

  • Weak: Revenue -7.0% year over year, -11.8% on the quarter
  • Weak: Gross margin 54.5%, -3.7 points on the quarter
  • Weak: Net loss $12M
  • Good: Cash generating: operating cash flow $177M, free cash flow $97M
  • Good: Share count -2.6% in a year: buying back
  • Weak: Net debt $4.62B · cash $451M
Revenue by quarter
Free cash flow
Net income
shares -2.6% in a year · net debt $4.6B
Final read
Growth: WEAK · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is revenue growth: revenue -7.0% year over year, -11.8% on the quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 3 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 bought new, 1 added.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Reported resultsFiling · 2026-11-11
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-07
above 20d & 50d on 2.9x volume at 90.38
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
Unusual volumeTape · 2026-11-07
5.7 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
GappedTape · 2026-11-05
+5.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-11-05
4.4 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Earnings comingEvent · 2026-11-04
reports 2026-11-05 amc
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Closed below its 20- and 50-day on heavy volumeTape · 2026-10-29
below 20d & 50d on 1.6x volume at 81.85
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
Closed below its 20- and 50-day on heavy volumeTape · 2026-10-24
below 20d & 50d on 1.7x volume at 85.41
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders

Nobody bought or sold on the open market in the last 6 months. There were 2 filings for awards, option exercises or shares withheld to pay tax — those happen on a vesting schedule, so they are not a decision to buy or sell.

Most recent filings
2026-09-01 Hanson Bryan C · Chief Executive Officer, Directoroption exercise67,261
2026-09-01 Hanson Bryan C · Chief Executive Officer, Directorwithheld for tax26,468$2,407,265

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy1
Buy7
Hold5
Sell1
Strong sell1

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Solventum Corporation (SOLV) — The Tape